Emergent Biosolutions INC Form 4 insider transactions

Emergent BioSolutions SVP, Products Business Paul Anthony Williams reported a sale of 3,000 common shares on July 1, 2026, executed under a pre-arranged 10b5-1 trading plan.

Paul Anthony Williams, SVP of Products Business at Emergent BioSolutions Inc., reported a transaction involving the withholding of shares to cover tax obligations.

Richard S. Lindahl, EVP and CFO of Emergent BioSolutions Inc., reported a transaction involving the withholding of shares to cover taxes related to restricted stock units.

Coleen Glessner, EVP at Emergent BioSolutions, reported a transaction involving the withholding of shares to cover taxes related to restricted stock units.

William Hartzel, SVP of Bioservices at Emergent BioSolutions Inc., reported a transaction involving the sale of 1,741 shares of common stock.

Emergent BioSolutions Director Sujata Tyagi Dayal reports transactions involving restricted stock units and stock options, including sales to cover tax obligations.

Donald W. DeGolyer, a Director at Emergent BioSolutions Inc., reported transactions involving the acquisition of restricted stock units and stock options, alongside the sale of common stock.

Emergent BioSolutions Director Keith Katkin reports transactions involving restricted stock units and stock options, including the acquisition of RSUs and the sale of shares to cover tax obligations.

Marvin L. White, a Director at Emergent BioSolutions Inc. (EBS), was granted restricted stock units and stock options on April 30, 2026, as part of his compensation for board service.

John D. Fowler Jr., a Director at Emergent BioSolutions Inc., was granted restricted stock units and stock options on April 30, 2026, as part of his compensation for board service.

Richard Ronald, a Director at Emergent BioSolutions Inc., was granted restricted stock units and stock options on April 30, 2026, as part of his compensation for board service.

Director Kathryn C. Zoon of Emergent BioSolutions Inc. (EBS) reported transactions involving restricted stock units and stock options, including the acquisition of RSUs and the sale of shares to cover tax obligations.

Emergent BioSolutions Inc. reports a stock grant and option award to Director Neal Franklin Fowler.

Emergent BioSolutions Inc. reports that Director Zsolt Harsanyi was granted restricted stock units and stock options on April 30, 2026, as part of his compensation for board service.

Paul Anthony Williams, SVP of Products Business at Emergent BioSolutions, was granted 100,111 restricted stock units following shareholder approval of the company's incentive plan.

Simon C. Lowry, SVP of R&D and CMO at Emergent BioSolutions, acquired 100,111 restricted stock units following shareholder approval of the company's incentive plan.

Coleen Glessner, EVP of Quality & Ethics at Emergent BioSolutions, was granted 100,111 restricted stock units following shareholder approval of the company's incentive plan.

CFO Richard S. Lindahl acquired 162,680 restricted stock units following shareholder approval of the company's incentive plan.

SVP and General Counsel Jessica Perl was granted 104,282 restricted stock units following shareholder approval of the company's incentive plan.

SVP of Bioservices William Hartzel was granted 100,111 restricted stock units following shareholder approval of the company's incentive plan.

CEO Joseph C. Papa acquired 187,708 restricted stock units following shareholder approval of the company's incentive plan.

Emergent BioSolutions SVP Paul Anthony Williams reported a sale of 4,000 shares of common stock on April 1, 2026, executed under a pre-arranged trading plan.

Emergent BioSolutions' EVP and CFO, Richard S. Lindahl, reported the expiration of unexercised employee stock options and a late Form 4 filing.

Emergent BioSolutions CEO Joseph C. Papa reported the acquisition of stock options and the disposition of shares for tax purposes.

Emergent BioSolutions Inc. Director John D. Fowler Jr. acquired 5,006 shares of common stock through a restricted stock unit grant.

Emergent BioSolutions SVP Simon Lowry reported the acquisition of new stock options and the sale of shares for tax purposes.

Emergent BioSolutions' SVP of Bioservices, William Hartzel, reported the acquisition of stock options and the disposition of shares for tax purposes.

Emergent BioSolutions SVP Jessica Perl reported the acquisition of stock options and the disposal of shares for tax withholding purposes.

Emergent BioSolutions' SVP, Paul Anthony Williams, reported the acquisition of stock options and the disposition of shares for tax purposes.

Emergent BioSolutions' EVP and CFO, Richard S. Lindahl, reported the acquisition of 72,856 employee stock options and the disposition of 23,650 common shares for tax purposes.